Autoantibodies and Autoantigens in Autoimmune Hepatitis

Christian P. Strassburg, MD, Michael P. Manns, MD


Semin Liver Dis. 2002;22(4) 

In This Article

Additional Autoantibodies in Autoimmune Hepatitis

The asialoglycoprotein receptor is a liver-specific glycoprotein of the cell membrane. Autoimmunity targeting this antigen is observed in 88% of AIH patients.[114] However, anti-ASGPR antibodies are also found in chronic hepatitis B and C, alcoholic liver disease, and PBC. The levels of anti-ASGPR antibodies vary according to inflammatory activity of the disease and could play a role as a marker to monitor therapeutic efficacy.[115] Anti-ASGPR appears to be a general marker of liver autoimmunity.

Anti-cytosol antibodies type 1 (anti-LC-1) antibodies are viewed as a second marker of AIH type 2, in which they have been detected in up to 50% of LKM-positive sera.[116] Other data indicate their occurrence in combination with ANA and SMA autoantibodies and also in chronic hepatitis C.[117] In contrast to LKM autoantibodies, LC-1 autoantibodies appear to correlate with disease activity. The molecular antigen target has been identified as formiminotransferase cyclodeaminase.[118] A clinical significance is not yet completely defined.

Antineutrophil cytoplasmic autoantibodies (ANCA) are detected 65 to 96% of sera.[119,120] pANCA are rare in AIH type 2. The role of ANCA in AIH is not clear, and their routine determination is not recommended.


Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.